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6/j.bSCOPE OF THE ISSUE
Successful immune suppression and modulation is
a cornerstone in the hematopoietic cell transplantation
(HCT) process. Only a limited number of active
immunosuppressive compounds are commonly used
in HCT. Despite the relatively limited number of
HCTs performed in the United States each year, there
is a multimillion dollar market for pharmaceutical
immunosuppressants, given the more extensive use of
these drugs in solid organ transplantation. As such,
an active generic immunosuppressant industry has
evolved over the past few years.
Clinical studies comparing outcomes from the use
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bmt.2010.11.006in HCT have not been performed, and the use of ge-
neric immunosuppressants has not been recommen-
ded or discouraged by the American Society of Blood
andMarrowTransplantation (ASBMT). In September
2009, the ASBMT’s Executive Committee convened
a Task Force to evaluate the use of generic immuno-
suppressants in HCT. The Task Force examined
issues of drug bioequivalence, drug safety, and phar-
macoeconomics in HCT and prepared this report by
consensus. Opinions were solicited from members of
the brand-name pharmaceutical industry, the generic
pharmaceutical industry, and the insurance industry,
as well as university-based healthcare economists and
researchers.GENERIC IMMUNOSUPPRESSANTS
Many different pharmaceutical companies pro-
duce generic immunosuppressant agents. At the time
of this writing, there are at least 8 generic versions of
mycophenolate mofetil (CellCept; Roche, San Fran-
cisco, CA) and 3 generic versions of tacrolimus (Pro-
graf; Astellas, Deefield, IL) on the market in the
United States (Figure 1). Numerous generic versions
of cyclosporine have been marketed for years, and
the transplantation community has long used generic
versions of prednisone without issues.
A generic drug product is one that is comparable to
a brand name drug product in dosage form, strength,
route of administration, quality, performance charac-
teristics, and intended use [1]. Generic drugs contain
active ingredients that are identical to the correspond-
ing brand-name formulations; sometimes the active
compound is even purchased from the same chemical
manufacturer. The differences between brand-name
and generic drugs lie in the excipients included in the
formulations, as well as in the physical composition
of the drug in pill, liquid, or i.v. formulations.
Generic medications are approved by the Food and
Drug Administration (FDA) through a process known
as an Abbreviated New Drug Application (ANDA).
The key to the ANDA approval process lies in285
Figure 1. Images of commercially available preparations of mycophenolate mofetil and tacrolimus, where available.
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neric drugs is governed by the Drug Price and Compe-
tition and Patent Term Restoration Act of 1984 (also
known as the Waxman-Hatch Act), an update to the
ANDA process initially promulgated in 1970 (de-
scribed in §21 CFR Parts 314 and 320). Evidence of bi-
oequivalence is often, if not exclusively, demonstrated
in normal volunteers, whereby the pharmacokinetics
(area under the curve [AUC] and peak concentration
[Cmax]/time to peak concentration [Tmax]) of single
or multiple doses of the generic compound are com-
pared with the brand-name compound in a crossoverfashion. Genericmanufacturers do not need to recapit-
ulate any phase I-III clinical tests that have already
been performed to demonstrate the safety and efficacy
of the brand-name drug to the FDA [2].
The statistical requirements for bioequivalence,
expressed as an average AUC or Cmax ratio of the ge-
neric compound to the brand-name compound, allow
up to 20% variability between brand-name and generic
compounds. Thus, using 90% confidence intervals,
a generic product may have pharmacokinetic proper-
ties anywhere between 80% and 125% (the inverse
of 80%) of those of the parent compound to fulfill
Biol Blood Marrow Transplant 17:285-290, 2011 287ASBMT Position Statementthe requirements for bioequivalence [3]. This wide
equivalence range represents the total variability of
the test subjects and is influenced by intersubject
variability during the testing phase, as well as the
variance of the bioanalytical assays used to measure
pharmacokinetics.
The FDA recently published a retrospective anal-
ysis of the bioequivalence testing of oral agents sub-
jected to the ANDA approval process over the last 12
years. In this analysis of 2070 bioequivalence assays,
the average differences in Cmax and AUC were
4.57% 6 3.59% and 3.17% 6 2.69%, respectively.
These variances were slightly lower when 1788
immediate-release–only formulations were examined
(4.43% 6 3.50% and 3.15% 6 2.66%, respectively).
The FDA found that 97.8% of the immediate-release
formulations had AUC differences of \10% [4].
Two recent systematic reviews and meta-analyses in
randomized controlled trials found no evidence of
a superiority of brand-name drugs over generic drugs
in terms of efficacy in treating cardiovascular disease
(including anticoagulation with warfarin) [5] or epi-
lepsy [6].
Anecdotal evidence has emerged of patients experi-
encing different outcomes on switching from brand-
name to generic products. Reports of possible clinical
differences between brand-name and generic drugs are
of particular concern for so-called ‘‘narrow therapeutic
index’’ (NTI) drugs, in which the effective and toxic
doses are separated by only a small difference in plasma
concentration [7,8]. Some immunosuppressants also fall
within this category of NTI drugs. It is important to
note that in the United States, no special additional
testing is generally required for NTI drugs, although
additional testing is required by other regulatory
agencies worldwide, such as Health Canada and the
European Medicines Agency [9]. For immunosuppres-
sants, however, the FDA has released guidance for the
testing of food effects on both tacrolimus and sirolimus
pharmacokinetics [10,11].
Given that the FDA approves generic drugs on the
basis of their pharmacokinetic equivalency, in some
circumstances, it may be important to demonstrate
pharmacodynamic and efficacy equivalency as well.
To date, however, neither brand-name nor generic
pharmaceutical manufacturers have engaged heavily
in these comparative trials.EXPERIENCE WITH GENERIC
IMMUNOSUPPRESSANTS IN NON-HCT
SETTINGS
Given the lack of prospective or even retrospective
analyses of outcomes related to the use of generic
drugs in HCT, the Task Force reviewed the
experience with other organ transplantation whenformulating this position paper. Because of the long
experience with alternate preparations of cyclosporine,
that drug is not reviewed here.Tacrolimus
The first generic tacrolimus preparation was intro-
duced to the US market in late 2009, and as such, data
on therapeutic conversion are limited. One small re-
port of 4 pediatric patients inadvertently switched
from brand-name to generic tacrolimus showed a sig-
nificant drop in tacrolimus trough levels in one patient
and acute rejection in another patient without a mean-
ingful change in serum levels [12]. More important is
a large multicenter study of generic tacrolimus conver-
sion in solid organ recipients. A total of 102 conver-
sions were reported, and 29% of the patients
required dosage titration. Approximately half of the
patients required upward dosage titrations, and the
other half required dosage reductions. Importantly,
average drug costs fell by $53-$77 per month, but
this did not account for the extra costs associated
with increased therapeutic drug monitoring [13].
One prospective trial has compared the brand-
name and alternative generic tacrolimus preparations
in de novo renal transplantation. This trial demon-
strated a near doubling of acute rejection episodes in
the 222 patients randomized to the alternative prepa-
ration. Patients in the alternative preparation group
had lower plasma drug levels compared with those in
the brand-name group, and this was the variable
most closely associated with acute rejection [14]. The
alternative compound used in that study was not offi-
cially a generic drug as defined in the United States,
because it had not been approved by the FDA. This
and other alternative preparations of tacrolimus, all
currently unavailable in the United States, have been
shown to have different physiochemical properties
than brand-name tacrolimus [15]. Other, nonrandom-
ized analyses of alternative tacrolimus preparations
have been published [16-18].Mycophenolate Mofetil
Even though generic mycophenolate mofetil was
introduced to the US market several years ago, the
lack of a defined serum therapeutic range has made
comparisons between brand name and generic com-
pound less relevant. In a small series of patients with
stable renal function after renal transplantation, 13 pa-
tients underwent pharmacokinetic studies after chang-
ing from brand-name to generic mycophenolate
mofetil. All pharmacokinetic studies except 2-hour se-
rum mycophenolic acid concentration were very simi-
lar in the brand-name and generic drugs. In addition,
serum creatinine levels remained unchanged at 12
months after the switch [19].
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SOCIETIES ON GENERIC
IMMUNOSUPPRESSANTS
Other societies and professional organizations
have issued their own recommendations regarding
the use of generic immunosuppressants in their respec-
tive fields. The American Society of Transplantation
has recommended further clinical trials of generic im-
munosuppressants in at-risk populations, specifically
African Americans and pediatric patients, as well as
education programs designed to encourage patients
to inform their healthcare providers of the substitution
of a generic drug for a brand-name drug [20]. Similar
recommendations have been put forth by the Interna-
tional Society for Heart and Lung Transplantation
[21]. The American Society of Nephrology does not
have a published position on the topic; however, the
National Kidney Foundation previously endorsed the
use of generic immunosuppressant drugs, largely on
the basis of the potential pharmacoeconomic benefits
of these agents, while similarly calling for increased
testing in transplantation subpopulations [22].SPECIFIC ISSUES IN HCT
InHCT, nearly all patients must contend with pol-
ypharmacy, and drug–drug interactions are often vari-
able and unpredictable. These drug interactions exist
between multiple immunosuppressants and supportive
care medications, such as antifungal agents.
In at least one series in solid organ transplantation,
differentiation between brand-name and generic cy-
closporine was determined based on drug interactions
with sirolimus [23]. This is relevant for medications
such as tacrolimus, for which drug levels can be mea-
sured and dosage modifications made as long as the
treating clinician is aware that a change in one drug
is made. However, there currently is no mechanism
to make clinicians aware of a therapeutic change in
drug supply. The consequences of these dosage
changes can be severe with respect to the level of the
changed drug as well as with potential interactions
with other drugs. Because generic drugs can have up
to a 20% difference in pharmacokinetic properties
with their brand-name counterparts (although such ex-
treme differences were not routinely observed in the
FDA study), a change from a generic drug with an an-
ticipated pharmacokinetic absorption profile 20%
lower than the brand-name drug to a generic drug
with an anticipated pharmacokinetic profile 20%
higher than the brand-name compound can lead to
considerable differences in serum drug concentrations.
Again, for drugs such as tacrolimus, as long as there
is forewarning, close monitoring of serum levels can
be initiated. However, for mycophenolate mofetil,
for which drug level monitoring is not routinelyperformed and an optimal therapeutic window is not
known, this change can have important clinical conse-
quences. Both changes from a brand-name to generic
formulation and from one generic formulation to an-
other generic formulation can have these unantici-
pated consequences. Similar changes in therapeutic
drug levels of supportive medications used in HCT
can occur as well, and measurement of these drugs in
the blood should be performed whenever possible.
One scenario of note relevant inHCT is the poten-
tial for a drug formulation change upon hospital dis-
charge after transplantation. Although patients are
likely to be provided a consistent formulation while
hospitalized, the first prescription in the outpatient
setting may be a different formulation. Because close
drug-level monitoring is often maintained after trans-
plantation, this is not likely to be associated with sig-
nificant periods of time at either subtherapeutic or
supratherapeutic drug levels, when measurable. In
general, drug-level monitoring should be done at least
once at approximately 1 week after a change in drug
formulation.PHARMACOECONOMIC AND SOCIETAL
PERSPECTIVES ON THE USE OF GENERIC
DRUGS IN HCT
The Task Force considered several other positions
when generating this report. These positions are from
two distinct groups: drug manufacturers (of both
brand-name and generic drugs) and the payers, a group
comprising individual patients, insurance agencies,
and the governmental healthcare support system.
From the patients’ standpoint, interventions that
reduce out-of-pocket costs through a reduction or
abatement of copayments for prescription drugs can
promote adherence to chronic medication therapy
[24]. In general, patients’ responsibilities for paying
for prescription medications generally decrease with
a change from brand-name to generic preparations,
because a tiered formulary is common in insurance
plans with prescription drug coverage. This was dem-
onstrated in the recent trial of a planned switch from
a brand-name to a generic drug in renal transplanta-
tion.13 Although not yet proven in HCT or organ
transplantation, it has been demonstrated in other
fields that copayments are significantly negatively
associated with prescription medication adherence
[25-27].
From the payers’ standpoint, any intervention that
reduces costs associated with healthcare delivery with-
out a change in patient outcomes is viewed favorably. A
reduction in medication costs for the insurer (or gov-
ernmental healthcare provider) could lead to greater
coverage for services previously not covered for
HCT patients as well as others in a similar situation.
However, if switching to generic immunosuppressants
Biol Blood Marrow Transplant 17:285-290, 2011 289ASBMT Position Statementwould require more intensive monitoring and/or lead
to higher rates of adverse events, then these higher
downstream costs could outweigh the initial cost
savings associated with the use of generic drugs.
Pharmaceutical companies engaged in research to
develop immunosuppressants for HCT stand to lose
the most as bioequivalent generic competitors are ap-
proved and become more widely used. Manufac-
turers’ substantial research and development costs
for future drugs are funded by revenues from cur-
rently marketed drugs, and thus the FDA has pro-
vided patent protection time periods meant to allow
pharmaceutical companies time to recover the costs
of drug development. On the other hand, market ex-
clusivity leading to higher prices for brand name
drugs should not be indefinite. Current legal limits
on patent length suggest that patients should be al-
lowed to enjoy enhanced access derived from the
availability of lower-cost generic drugs after a certain
period. It is beyond the scope of this Task Force to
comment further on the issues of the duration of
patent protection and cost recovery.RECOMMENDATIONS OF THE TASK FORCE
1. Patient education. Patients should be educated
on the possibility that their immunosuppressant med-
ications could be altered in shape, size, or color. They
should be educated that the FDA approves generic
drugs as being bioequivalent to brand name products,
and that there is no evidence suggesting that brand
name drugs are superior. However, patients also
should be encouraged to inform their healthcare pro-
viders of any change in their immunosuppressant
drugs. Figure 1 should be provided to patients, made
available on the ASBMT Web site for providers, and
periodically updated when new drug formulations are
approved for use.
2. Consistent use of one drug formulation. Pro-
viders should attempt to use only one formulation of
an immunosuppressant drug, either consistently pre-
scribing a brand name or a generic formulation, to re-
duce the possibility of changes in drug levels.
Specifying which generic formulation in a prescription
might not be feasible, however, given that a pharmacy
is likely to only carry one generic formulation at a time.
HCT physicians also should be encouraged to engage
patients in conversations about their drug costs and the
financial burden of these costs. If such a discussion
suggests a concern for reduced adherence due to
continued prescription of a more costly brand name
formulation, then a monitored switch to a generic
version should be encouraged.
3. Enhanced monitoring after formulation
changes. Whenever patients change drug formula-
tions, either between brand name and generic formula-
tions or between two generic formulations, drug levelsshould be monitored, preferably after several half-lives
of the drug have passed. In general, monitoring at least
1 week from the time of a formulation change should
be sufficient.
4. Clinical trials. Clinical trials for equivalence,
focusing on graft-versus-host disease and related out-
comes, should be encouraged. Well-controlled obser-
vational trials also may provide insight into the
question of the clinical equivalence of brand name
and generic immunosuppressants. Individual drug
levels, although relevant, are less important than
trends and associations with poorer control of the ad-
verse immunologic consequences of HCT.
5. Analysis of true cost. Although generic drugs
may have lower retail costs and lower insurance copay-
ments compared with brand-name drugs, studies of
the true cost of these substitutions, including the costs
associated with increased drug monitoring and the po-
tential costs of adverse events associated with altered
drug levels, should be performed to determine the
financial implications of the use of generic immuno-
suppressants in HCT.ACKNOWLEDGMENTS
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